Literature DB >> 9003836

Elevated tumor-associated antigen CA 19-9 in a patient with an enlarged pancreas: does it always imply malignancy?

B A Tolliver1, B L O'Brien.   

Abstract

Carbohydrate antigen 19-9 (CA 19-9) has been used as a serum tumor marker for adenocarcinoma of the upper gastrointestinal tract, particularly primary adenocarcinoma of the pancreas. This tumor marker has also been used to differentiate benign from malignant diseases of the pancreas. However, significant elevations of CA 19-9 levels in the absence of pancreatic malignancy have also been reported. This case illustrates a marked elevation of CA 19-9 due to an infectious process in a patient with a pancreatic mass suggestive of malignancy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9003836     DOI: 10.1097/00007611-199701000-00023

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

1.  Extremely elevated CA19-9 in acute cholangitis.

Authors:  Shyr-Ming Sheen-Chen; Cheuk-Kwan Sun; Yei-Wei Liu; Hock-Liew Eng; Sheung-Fat Ko; Chung-Huang Kuo
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

2.  Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker.

Authors:  Mao-Song Lin; Jun-Xing Huang; Hong Yu
Journal:  Int J Clin Exp Med       Date:  2014-03-15

3.  Endoscopic ultrasonography in patients with elevated carbohydrate antigen 19-9 of obscure origin.

Authors:  Jae Hoon Cheong; Gwang Ha Kim; Ji Yoon Moon; Bong Eun Lee; Dong Yup Ryu; Dong Uk Kim; Hyung-Il Seo; Geun Am Song
Journal:  World J Gastrointest Endosc       Date:  2013-05-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.